Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The company expects that this development could improve the strength of its application to the FDA for new drug approval
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
WINLEVI works differently from any other topical acne treatment
India is promoting holistic healthcare with emphasis on preventive care
The campus in Genome Valley will provide services in discovery chemistry & discovery biology, safety toxicology, bioanalytical services and formulation development to global pharmaceutical companies
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
Subscribe To Our Newsletter & Stay Updated
